New Australian legislation will improve access to medicines and cut red-tape

2 December 2016
canberra-big

Legislation introduced to Parliament on the final sitting day of 2016 will enable faster access to certain new medicines for Australian patients and help to cut unnecessary red tape for industry too.

The Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016 was introduced by Health Minister Sussan Ley, and is the first legislative step toward the full implementation of the Medicines and Medical Devices Review.

The bill includes measures which support the introduction of new expedited pathways for the marketing approval of certain medicines and medical devices, by providing a regulation-making power to set out the details of the new pathways for priority review, Ms Ley noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical